Biohacker Bryan Johnson, known for his extreme anti-aging experiments, has launched his latest longevity protocol. In a recent social media post, he stated that he has started microdosing GLP-1 medications typically prescribed for diabetes and weight loss.
The tech entrepreneur began testing ultra-low doses of tirzepatide in December 2024, seeking to harness potential anti-aging benefits while avoiding unwanted side effects.
Johnson’s approach involves taking just 0.5 mg weekly of tirzepatide. It is half the typical microdose and one-fifth the standard starting dose for diabetes treatment.
“As someone already metabolically healthy and in the lowest 1% of body fat content, my goal isn’t weight loss,” Johnson explained. “Microdosing allows me to harness the potential longevity benefits of GLP-1RA while minimizing side effects and avoiding unwanted weight or muscle loss.”
The decision stems from emerging research suggesting GLP-1 receptor agonists offer benefits beyond blood sugar control and appetite suppression. Johnson points to studies indicating these medications may reduce Alzheimer’s disease risk, decrease systemic inflammation, and potentially reverse biological aging across multiple organs—effects that appear independent of weight loss.
However, the experiment hasn’t been without trade-offs. Johnson discovered that his microdose increased his resting heart rate by 3 beats per minute and lowered his heart rate variability by 7 points.
“GLP-1’s raise your resting rate which can degrade sleep quality and lower HRV,” he noted, sharing data showing different GLP-1 cause varying degrees of heart rate elevation.
The longevity enthusiast chose tirzepatide specifically because it activates both GLP-1 and GIP receptors, creating what researchers describe as synergistic effects for cardiovascular protection and metabolic optimization. His protocol aims to achieve several longevity-focused outcomes: reduced glucose spikes and insulin levels, enhanced mitochondrial function, decreased inflammation, and mimicry of caloric restriction’s metabolic benefits.
Johnson’s 12-week trial includes comprehensive monitoring to track potential benefits and risks. He’s measuring metabolic markers like continuous glucose levels and insulin sensitivity, inflammatory indicators including hs-CRP and IL-6, and biological age through epigenetic clocks. Body composition scans will ensure he doesn’t lose muscle mass or facial fat—a common concern with GLP-1.
The approach reflects Johnson’s characteristic methodology of self-experimentation with emerging interventions. While GLP-1 have shown promise in clinical studies for reducing cardiovascular disease risk and potentially preventing age-related conditions, their use in healthy individuals for longevity purposes remains largely uncharted territory.
Johnson acknowledges several risks requiring careful monitoring, including gastrointestinal issues, unintended weight loss, and potential muscle wasting. However, he believes his precisely calculated nutrition protocol will help mitigate concerns about protein deficiency that typically accompany GLP-1 use.
The entrepreneur plans to share his complete results after the 12-week trial concludes.
